Larry D. Anderson

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Nikhil C. Munshi, Larry D. Anderson, Nina Shah et al. · New England Journal of Medicine · 2021 · 2.4K citations · Full text

Medicine, Hematology, Oncology +17

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Peter M. Voorhees, Jonathan L. Kaufman, Jacob P. Laubach et al. · Blood · 2020 · 690 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

Paul G. Richardson, Susanna Jacobus, Edie Weller et al. · New England Journal of Medicine · 2022 · 463 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 385 citations · Full text

Medicine, Hematology, Pharmacotherapy +11

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

Sebastian Grosicki, Maryana Simonova, Ivan Špıčka et al. · The Lancet · 2020 · 324 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16